News

Innoviva Specialty Therapeutics Announces IDWeek 2024 Presentations

Innoviva Specialty Therapeutics Announces IDWeek 2024 Presentations

Innoviva Specialty Therapeutics Unveils Clinical Insights at IDWeek 2024

Innoviva Specialty Therapeutics, a prominent biotech firm dedicated to breakthroughs in critical care and infectious diseases, is set to highlight its latest clinical advancements at the upcoming IDWeek 2024. This annual gathering is a cornerstone event for professionals tackling infectious diseases, occurring between October 16-19, 2024. The event will be held in Los Angeles, California, where Innoviva Specialty Therapeutics aims to present three clinical abstracts and conduct two significant oral presentations.

Key Clinical Insights from the Pipeline

David Altarac, MD, Chief Medical Officer at Innoviva Specialty Therapeutics, expressed excitement about the latest findings from their comprehensive clinical program. He stated, "Our clinical program continues to provide crucial insights from recent sub-analyses that deliver meaningful enhancements for healthcare professionals dealing with challenging antimicrobial-resistant pathogens." One of the highlights of their pipeline is zoliflodacin, which recently completed a pivotal phase 3 trial in collaboration with the Global Antibiotics Research Development Partnership. If regulatory approval is achieved, zoliflodacin could emerge as the first novel oral antibiotic for gonorrhea in decades.

Oral Presentations at IDWeek 2024

The first notable oral presentation will occur on Friday, October 18, where Dr. Altarac will discuss a growing global challenge and how a novel public-private partnership is addressing it. This presentation is timed for 8:00 am – 9:00 am PT in Petree C. The second oral presentation on Saturday, October 19, will focus on the activity of sulbactam-durlobactam in combating Acinetobacter baumannii complexities among hospitalized patients, scheduled from 10:54 am to 11:06 am PT in Room 403A.

Comprehensive Poster Sessions

In addition to the oral presentations, the company will present several posters emphasizing their innovative research. For instance, Poster #P-1103 will detail the in vitro activity of zoliflodacin against baseline Neisseria gonorrhoeae isolates in a pivotal phase 3 randomized controlled trial. Presentations will be held on Friday, October 18, during lunch hours in Hall J&K.

Pharmacometric Analyses and Surveillance

Another significant presentation, Poster #P-1251, will provide essential pharmacometric analyses aimed at supporting dose selection for zoliflodacin, a pioneering oral antibiotic designed for uncomplicated gonorrhea. It will also share insights into the surveillance of eravacycline's effectiveness against clinical pathogens globally, reflecting data collected over four years from various infection sites. This last poster session will occur concurrently in Hall J&K.

About Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics operates as a subsidiary of Innoviva, Inc. The company's mission centers on delivering leading-edge therapies in both critical care and infectious disease sectors. Through its affiliations, including La Jolla Pharmaceutical Company and Entasis Therapeutics Inc., Innoviva's product lineup includes therapies such as GIAPREZA, designed to elevate blood pressure in adults experiencing septic or other forms of shock, and XERAVA, aimed at managing complicated intra-abdominal infections. Another notable product, XACDURO, is specially formulated for treating adults with pneumonia stemming from specific strains of Acinetobacter baumannii.

For further insights into Innoviva Specialty Therapeutics and its innovative offerings, interested parties are encouraged to explore their official website.

Frequently Asked Questions

What is IDWeek 2024?

IDWeek 2024 is an annual event focusing on infectious diseases, where researchers and healthcare professionals gather to present and discuss recent advancements in the field.

What will Innoviva Specialty Therapeutics present at IDWeek 2024?

They will present data from three clinical abstracts and conduct two significant oral presentations regarding their innovative therapies.

Who is Dr. David Altarac?

Dr. David Altarac is the Chief Medical Officer at Innoviva Specialty Therapeutics and will be one of the key speakers at IDWeek 2024.

What is zoliflodacin?

Zoliflodacin is a investigational oral antibiotic being developed to treat gonorrhea, potentially marking the first new treatment option in decades.

Where can I find more information about Innoviva Specialty Therapeutics?

For more details about their products and ongoing research, you can visit Innoviva Specialty Therapeutics' official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 104

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 87

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Purdue's xGTT: Pioneering a New Trust Standard in Tech

Updated Category News Views 150

A Bold New Benchmark in Tech Trust You've got to hand it to the folks at Purdue's Krach Institute—they're not dancing around the fringes but diving straight into the thick of it with their Global Trusted Tech Standard, or xGTT. This isn't just another checkbox for compliance nerds. The xGTT is all about building trust in technology that's woven with democratic values...

Continue Reading
CVRx Faces Legal Storm: Investors Grapple with Fallout

Updated Category News Views 150

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 108

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Interactive Donor Recognition: Beyond GivingTuesday

Updated Category News Views 98

Crafting Stories That Endure You ever notice how some things just fade away after the holidays? Schools don't want their donor stories to go out like last year's tinsel. Rocket Alumni Solutions strikes right at the core of this concern. They recommend crafting donor recognition that lasts beyond GivingTuesday, by anchoring the story in the school's community. This isn't...

Continue Reading
Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 162

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions

Updated Category News Views 117

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Continue Reading
Backdoor Reference Checks: A Hiring Minefield?

Updated Category News Views 157

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

Continue Reading
Optikos Secures CMMC Level 2, Eyeing Defense Market

Updated Category News Views 116

Optikos Levels Up with CMMC Certification In a world where cybersecurity threats are lurking around every corner, Optikos has just joined the rarefied ranks of the top 1% of U.S. defense suppliers by grabbing the CMMC Level 2 certification. Let me tell you, this isn't just some shiny badge for show; it's a gateway to big defense contracts. Crunching the Numbers Of the...

Continue Reading

Top 5 Most Recently Viewed Articles

IHS Holding's Deal: Fair Price or Insider Play?

Updated Category News Views 170

IHS Holding (NYSE: IHS) just got slapped with an investigation from Ademi LLP over possible breaches of fiduciary duty in their recent $6.2 billion transaction with MTN Group Limited. Let’s break this down—traders are already fuming about what’s cooking under the surface. Insider Gains: Who Wins? The crux here is that shareholders will pocket a measly $8.50 per...

Continue Reading
PLAY Airlines Achieves Record Load Factor and Revenue Growth

Updated Category News Views 248

PLAY Airlines Reports Record-Breaking Load Factor for November PLAY Airlines has announced that it carried an impressive 99,393 passengers in the month of November, showcasing its operational efficiency and strategic adaptations. Although this is a decrease from the 107,236 passengers flown in the same month in the previous year, this is largely attributed to a 17%...

Continue Reading
Tempus Collaborates with Northwestern Medicine to Enhance AI Use in Care

Updated Category News Views 122

Tempus Teams Up with Northwestern Medicine to Transform Healthcare Tempus, a frontrunner in the realm of artificial intelligence and precision medicine, has announced a significant collaboration with Northwestern Medicine, noted for being a leading integrated academic health system. This partnership is tailored to investigate the practical applications of artificial...

Continue Reading
Investor Insights: May's Most Influential Announcements

Updated Category News Views 28

The Sky's the Limit with United's Spirit Chase Kicking off May with a twist, United Airlines threw out a bone to Spirit Airline's distressed travelers. For those whose flights were axed, United dangled capped-price tickets as a lifeline. Maybe it's about garnering goodwill, maybe it's swiping market slice—either way, United's move isn't just about customer care....

Continue Reading
Fountainful Partners with SFSG for Timeless Bench Installation

Updated Category News Views 179

Fountainful Partners with Sculpture Garden for Bench Installation Fountainful is thrilled to announce its collaboration with the Saint Francis Sculpture Garden (SFSG) on a long-term bench installation project. When discussions began about replacing outdated wooden benches, it sparked excitement within Fountainful. Donna Shatter, a managing partner of Fountainful,...

Continue Reading